vs
礼蓝动物保健（ELAN）与FactSet（FDS）财务数据对比。点击上方公司名可切换其他公司
礼蓝动物保健的季度营收约是FactSet的1.9倍（$1.1B vs $607.6M），FactSet净利率更高（25.1% vs -24.1%，领先49.2%），礼蓝动物保健同比增速更快（12.2% vs 6.9%），FactSet自由现金流更多（$90.4M vs $46.0M），过去两年FactSet的营收复合增速更高（5.5% vs -2.6%）
礼蓝动物保健是一家美国动物保健制药企业，专注于生产宠物及家畜用药品与疫苗。该公司原为礼来公司旗下子公司，2019年完成分拆独立，目前是全球第三大动物保健企业。
FactSet是总部位于美国康涅狄格州诺沃克的金融数据与软件企业，为客户提供一体化数据及软件解决方案。2024财年，公司年度订阅价值与专业服务营收合计22亿美元，当前总市值约170亿美元。
ELAN vs FDS — 直观对比
营收规模更大
ELAN
是对方的1.9倍
$607.6M
营收增速更快
ELAN
高出5.3%
6.9%
净利率更高
FDS
高出49.2%
-24.1%
自由现金流更多
FDS
多$44.4M
$46.0M
两年增速更快
FDS
近两年复合增速
-2.6%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $607.6M |
| 净利润 | $-276.0M | $152.6M |
| 毛利率 | 51.5% | 52.6% |
| 营业利润率 | -22.6% | 31.6% |
| 净利率 | -24.1% | 25.1% |
| 营收同比 | 12.2% | 6.9% |
| 净利润同比 | -3350.0% | 1.7% |
| 每股收益（稀释后） | $-0.55 | $4.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ELANFDS
| Q4 25 | $1.1B | $607.6M | ||
| Q3 25 | $1.1B | $596.9M | ||
| Q2 25 | $1.2B | $585.5M | ||
| Q1 25 | $1.2B | $570.7M | ||
| Q4 24 | $1.0B | $568.7M | ||
| Q3 24 | $1.0B | $562.2M | ||
| Q2 24 | $1.2B | $552.7M | ||
| Q1 24 | $1.2B | $545.9M |
净利润ELANFDS
| Q4 25 | $-276.0M | $152.6M | ||
| Q3 25 | $-34.0M | $153.6M | ||
| Q2 25 | $11.0M | $148.5M | ||
| Q1 25 | $67.0M | $144.9M | ||
| Q4 24 | $-8.0M | $150.0M | ||
| Q3 24 | $364.0M | $89.5M | ||
| Q2 24 | $-50.0M | $158.1M | ||
| Q1 24 | $32.0M | $140.9M |
毛利率ELANFDS
| Q4 25 | 51.5% | 52.6% | ||
| Q3 25 | 53.4% | 51.6% | ||
| Q2 25 | 57.5% | 52.1% | ||
| Q1 25 | 57.3% | 52.8% | ||
| Q4 24 | 50.9% | 54.5% | ||
| Q3 24 | 52.2% | 54.1% | ||
| Q2 24 | 58.2% | 55.3% | ||
| Q1 24 | 57.3% | 53.3% |
营业利润率ELANFDS
| Q4 25 | -22.6% | 31.6% | ||
| Q3 25 | -4.4% | 29.7% | ||
| Q2 25 | 2.0% | 33.2% | ||
| Q1 25 | 5.0% | 32.5% | ||
| Q4 24 | -5.0% | 33.6% | ||
| Q3 24 | 54.3% | 22.7% | ||
| Q2 24 | -2.7% | 36.6% | ||
| Q1 24 | 1.0% | 33.3% |
净利率ELANFDS
| Q4 25 | -24.1% | 25.1% | ||
| Q3 25 | -3.0% | 25.7% | ||
| Q2 25 | 0.9% | 25.4% | ||
| Q1 25 | 5.6% | 25.4% | ||
| Q4 24 | -0.8% | 26.4% | ||
| Q3 24 | 35.3% | 15.9% | ||
| Q2 24 | -4.2% | 28.6% | ||
| Q1 24 | 2.7% | 25.8% |
每股收益（稀释后）ELANFDS
| Q4 25 | $-0.55 | $4.06 | ||
| Q3 25 | $-0.07 | $4.03 | ||
| Q2 25 | $0.02 | $3.87 | ||
| Q1 25 | $0.13 | $3.76 | ||
| Q4 24 | $-0.01 | $3.89 | ||
| Q3 24 | $0.73 | $2.33 | ||
| Q2 24 | $-0.10 | $4.09 | ||
| Q1 24 | $0.06 | $3.65 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $545.0M | $292.7M |
| 总债务越低越好 | $3.9B | $1.4B |
| 股东权益账面价值 | $6.5B | $2.2B |
| 总资产 | $13.4B | $4.2B |
| 负债/权益比越低杠杆越低 | 0.60× | 0.63× |
8季度趋势，按日历期对齐
现金及短期投资ELANFDS
| Q4 25 | $545.0M | $292.7M | ||
| Q3 25 | $505.0M | $355.1M | ||
| Q2 25 | $539.0M | $364.0M | ||
| Q1 25 | $487.0M | $287.0M | ||
| Q4 24 | $468.0M | $358.8M | ||
| Q3 24 | $490.0M | $492.6M | ||
| Q2 24 | $416.0M | $522.0M | ||
| Q1 24 | $345.0M | $450.2M |
总债务ELANFDS
| Q4 25 | $3.9B | $1.4B | ||
| Q3 25 | $4.0B | $1.4B | ||
| Q2 25 | $4.1B | $1.4B | ||
| Q1 25 | $4.4B | $1.5B | ||
| Q4 24 | $4.3B | $1.4B | ||
| Q3 24 | $4.4B | $1.4B | ||
| Q2 24 | $5.7B | $1.4B | ||
| Q1 24 | $5.8B | $1.5B |
股东权益ELANFDS
| Q4 25 | $6.5B | $2.2B | ||
| Q3 25 | $6.7B | $2.2B | ||
| Q2 25 | $6.8B | $2.2B | ||
| Q1 25 | $6.4B | $2.1B | ||
| Q4 24 | $6.1B | $2.0B | ||
| Q3 24 | $6.5B | $1.9B | ||
| Q2 24 | $5.9B | $1.9B | ||
| Q1 24 | $6.1B | $1.8B |
总资产ELANFDS
| Q4 25 | $13.4B | $4.2B | ||
| Q3 25 | $13.6B | $4.3B | ||
| Q2 25 | $13.7B | $4.3B | ||
| Q1 25 | $12.9B | $4.2B | ||
| Q4 24 | $12.6B | $4.0B | ||
| Q3 24 | $13.3B | $4.1B | ||
| Q2 24 | $13.8B | $4.0B | ||
| Q1 24 | $14.0B | $4.0B |
负债/权益比ELANFDS
| Q4 25 | 0.60× | 0.63× | ||
| Q3 25 | 0.59× | 0.63× | ||
| Q2 25 | 0.61× | 0.66× | ||
| Q1 25 | 0.69× | 0.72× | ||
| Q4 24 | 0.70× | 0.68× | ||
| Q3 24 | 0.67× | 0.71× | ||
| Q2 24 | 0.96× | 0.76× | ||
| Q1 24 | 0.95× | 0.83× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $108.0M | $121.3M |
| 自由现金流经营现金流 - 资本支出 | $46.0M | $90.4M |
| 自由现金流率自由现金流/营收 | 4.0% | 14.9% |
| 资本支出强度资本支出/营收 | 5.4% | 5.1% |
| 现金转化率经营现金流/净利润 | — | 0.79× |
| 过去12个月自由现金流最近4个季度 | $284.0M | $647.4M |
8季度趋势，按日历期对齐
经营现金流ELANFDS
| Q4 25 | $108.0M | $121.3M | ||
| Q3 25 | $219.0M | $212.1M | ||
| Q2 25 | $237.0M | $253.8M | ||
| Q1 25 | $-4.0M | $174.0M | ||
| Q4 24 | $177.0M | $86.4M | ||
| Q3 24 | $162.0M | $163.2M | ||
| Q2 24 | $200.0M | $238.2M | ||
| Q1 24 | $2.0M | $143.8M |
自由现金流ELANFDS
| Q4 25 | $46.0M | $90.4M | ||
| Q3 25 | $127.0M | $178.1M | ||
| Q2 25 | $180.0M | $228.6M | ||
| Q1 25 | $-69.0M | $150.2M | ||
| Q4 24 | $130.0M | $60.5M | ||
| Q3 24 | $120.0M | $137.2M | ||
| Q2 24 | $166.0M | $216.9M | ||
| Q1 24 | $-22.0M | $121.9M |
自由现金流率ELANFDS
| Q4 25 | 4.0% | 14.9% | ||
| Q3 25 | 11.2% | 29.8% | ||
| Q2 25 | 14.5% | 39.0% | ||
| Q1 25 | -5.8% | 26.3% | ||
| Q4 24 | 12.7% | 10.6% | ||
| Q3 24 | 11.7% | 24.4% | ||
| Q2 24 | 14.0% | 39.2% | ||
| Q1 24 | -1.8% | 22.3% |
资本支出强度ELANFDS
| Q4 25 | 5.4% | 5.1% | ||
| Q3 25 | 8.1% | 5.7% | ||
| Q2 25 | 4.6% | 4.3% | ||
| Q1 25 | 5.4% | 4.2% | ||
| Q4 24 | 4.6% | 4.5% | ||
| Q3 24 | 4.1% | 4.6% | ||
| Q2 24 | 2.9% | 3.9% | ||
| Q1 24 | 2.0% | 4.0% |
现金转化率ELANFDS
| Q4 25 | — | 0.79× | ||
| Q3 25 | — | 1.38× | ||
| Q2 25 | 21.55× | 1.71× | ||
| Q1 25 | -0.06× | 1.20× | ||
| Q4 24 | — | 0.58× | ||
| Q3 24 | 0.45× | 1.82× | ||
| Q2 24 | — | 1.51× | ||
| Q1 24 | 0.06× | 1.02× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ELAN
| Pet Health | $489.0M | 43% |
| Cattle | $296.0M | 26% |
| Poultry | $237.0M | 21% |
| Swine | $107.0M | 9% |
| Contract Manufacturing | $15.0M | 1% |
FDS
| Americas Segment | $399.7M | 66% |
| EMEA Segment | $149.1M | 25% |
| Asia Pacific Segment | $62.2M | 10% |
